ReViral – Innovative therapies for viral diseases
ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds.
The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion RV521 which has completed its Phase 1 clinical studies and has shown significant activity in phase 2 clinical studies in adult volunteers. RV521 is now moving towards phase 2 studies in infant and adult patients.
Company Details
- Employees
- 5
- Address
- Gunnels Wood Road, Stevenage,hertfordshire Sg1 2fx,united Kingdom
- Phone
- 44 29 2078 1795
- in****@****l.co.uk
- Industry
- Biotechnology
- Website
- reviral.co.uk
- HQ
- Stevenage, Hertfordshire
Reviral Questions
Reviral's helpline number is 44 29 2078 1795
Reviral's website is reviral.co.uk
Reviral's LinkedIn profile is https://www.linkedin.com/company/reviral
Reviral has
5 employees.
View email and phone details for 5
employees at Reviral.
Reviral's industry is
Biotechnology
Reviral's top competitors are
Bamboo Therapeutics, Inc. A Wholly Owned Subsidiary Of Pfizer Inc.,
Lucira Health,
Pfizer,
Anacor Pharmaceuticals,
Seagen,
Novartis,
Medivation,
Gsk,
Hospira,
Global Blood Therapeutics.
Reviral's support email address is info@reviral.co.uk
Reviral's categories are Biotechnology
